Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07305818 · ClinicalTrials.gov registry record · Phase 1
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
A Phase 1 study of Graves Disease, sponsored by Merida Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT07305818: Recruiting Phase 1 study of Graves Disease, sponsored by Merida Biosciences.
NCT07305818 is a Phase 1 study of Graves Disease that is actively recruiting participants, run by Merida Biosciences. The registered enrollment target is 100 participants, below the 301-participant average among 11 other Graves Disease trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07305818, a Phase 1 study of Graves Disease, is actively recruiting participants, sponsored by Merida Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Primary Outcome
Adverse events that start or worsen in severity after the start of study drug will be categorized as TEAEs
Conditions Studied
Interventions
- BIOLOGICAL MER511 (IV)
- BIOLOGICAL Placebo comparator (IV)
- BIOLOGICAL MER511 (SC)
- BIOLOGICAL Placebo comparator (SC)
- BIOLOGICAL MER511 (SC) for MAD
Study Locations (3)
Arizona
- Site # 1103 - Phoenix
Florida
- Site # 1101 - Hollywood
Texas
- Site # 1105 - Webster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2028-07-24 |
| Phase | Phase 1 |
What NCT07305818 shows while recruiting
NCT07305818 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 301-participant average among 11 other Graves Disease trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Graves Disease appearing as the primary indexed condition, and to 5 interventions - of which MER511 (IV) is the first listed.
NCT07305818 reports a single indexed study location in Arizona, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07305818 about?
NCT07305818 is a clinical study titled "NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease". The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigat...
What is the current status of trial NCT07305818?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-12-19. Estimated completion is 2028-07-24.
What conditions does trial NCT07305818 study?
This clinical trial studies the following conditions: Graves Disease.
What interventions are being tested in trial NCT07305818?
The interventions under investigation include: MER511 (IV) (BIOLOGICAL), Placebo comparator (IV) (BIOLOGICAL), MER511 (SC) (BIOLOGICAL), Placebo comparator (SC) (BIOLOGICAL), MER511 (SC) for MAD (BIOLOGICAL).
Who is sponsoring clinical trial NCT07305818?
This trial is sponsored by Merida Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07305818 being conducted?
This trial has 3 study locations across Arizona, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graves Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07305818's enrollment target sits among peer trials
100 4th of 11 higher than 7 of 11 other Graves Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graves Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of BHV-1300 in Graves' Disease
RECRUITING · Phase 1
-
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
RECRUITING · Phase 2
-
Personalized Treatment in Thyroid Disorders
RECRUITING · NA
-
Preoperative Corticosteroids in Autoimmune Thyroid Disease
RECRUITING · Phase 4
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
-
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI